Regulatory T cells (Tregs) represent a low number of Tâcell population under normal conditions, and they play key roles for maintaining immune system in homeostasis. The number of these cells is extensively increased in nearly all cancers, which is for dampening responses from immune system against cancer cells, metastasis, tumor recurrence, and treatment resistance. The interesting point is that apoptotic Tregs are stronger than their live counterparts for suppressing responses from immune system. Tregs within the tumor microenvironment have extensive positive crossâtalks with other immunosuppressive cells including cancerâassociated fibroblasts, cancer cells, macrophage type 2 cells, and myeloidâderived suppressor cells, and they have negative interactions with immunostimulatory cells including cytotoxic T lymphocytes (CTL) and natural killer cells. A wide variety of markers are expressed in Tregs, among them forkhead box P3 (FOXP3) is the most specific marker and the master regulator of these cells. Multiple signals are activated by Tregs including transforming growth factorâβ, signal transducer and activator of transcription, and mTORC1. Treg reprogramming from an immunosuppressive to immunostimulatory proinflammatory phenotype is critical for increasing the efficacy of immunotherapy. This would be applicable through selective suppression of tumorâbearing receptors in Tregs, including FOXP3, programmed deathâ1, Tâcell immunoglobulin mucinâ3, and CTLâassociated antigenâ4, among others. Intratumoral Tregs can also be targeted by increasing the ratio for CTL/Treg.